Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, United States.
Curr Opin Virol. 2012 Aug;2(4):482-8. doi: 10.1016/j.coviro.2012.06.005. Epub 2012 Jul 12.
Infection of Kaposi sarcoma-associated herpesvirus (KSHV) or human herpesvirus-8 (HHV-8) is estimated to account for 34,000 new cancer cases globally. Unlike other herpesviruses, KSHV is not ubiquitous but is highly prevalent in some areas, such as sub-Saharan Africa where Kaposi sarcoma is the leading cancer among adults. While latent infection of KSHV plays a major and direct role in tumorigenesis, viral lytic replication also makes significant contributions to this process. Efforts to develop a KSHV vaccine are limited, but studies with EBV have provided important lessons. Informative vaccine research has been conducted in the mouse infection model of a closely related rodent virus, murine gammaherpesvirus-68 (MHV-68 or γHV-68). This mouse model has generated fundamental principles for an effective vaccination strategy. KSHV vaccines designed to prevent a naïve host from infection and to boost the immune control of KSHV in persistently infected people will have major impact on individuals who are at a high risk of developing KSHV-associated diseases.
卡波济肉瘤相关疱疹病毒（KSHV）或人类疱疹病毒 8 型（HHV-8）的感染估计在全球造成 34000 例新的癌症病例。与其他疱疹病毒不同，KSHV 并非无处不在，而是在某些地区高度流行，例如撒哈拉以南非洲，那里卡波济肉瘤是成年人中主要的癌症。虽然 KSHV 的潜伏感染在肿瘤发生中起主要和直接作用，但病毒裂解复制也对此过程有重大贡献。开发 KSHV 疫苗的努力受到限制，但 EBV 的研究提供了重要的经验教训。在密切相关的啮齿动物病毒鼠γ疱疹病毒-68（MHV-68 或γHV-68）的小鼠感染模型中进行了有意义的疫苗研究。该小鼠模型为有效的疫苗接种策略提供了基本原理。旨在预防宿主初次感染并增强潜伏感染个体对 KSHV 免疫控制的 KSHV 疫苗，将对那些处于发生 KSHV 相关疾病高风险的个体产生重大影响。
